GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Abiomed Inc (NAS:ABMD) » Definitions » EV-to-EBIT

Abiomed (Abiomed) EV-to-EBIT : 64.38 (As of May. 03, 2024)


View and export this data going back to 1987. Start your Free Trial

What is Abiomed EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Abiomed's Enterprise Value is $16,360 Mil. Abiomed's EBIT for the trailing twelve months (TTM) ended in Sep. 2022 was $254 Mil. Therefore, Abiomed's EV-to-EBIT for today is 64.38.

The historical rank and industry rank for Abiomed's EV-to-EBIT or its related term are showing as below:

ABMD' s EV-to-EBIT Range Over the Past 10 Years
Min: 22.03   Med: 63.09   Max: 694.68
Current: 64.38

During the past 13 years, the highest EV-to-EBIT of Abiomed was 694.68. The lowest was 22.03. And the median was 63.09.

ABMD's EV-to-EBIT is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 20.01 vs ABMD: 64.38

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Abiomed's Enterprise Value for the quarter that ended in Sep. 2022 was $10,277 Mil. Abiomed's EBIT for the trailing twelve months (TTM) ended in Sep. 2022 was $254 Mil. Abiomed's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2022 was 2.47%.


Abiomed EV-to-EBIT Historical Data

The historical data trend for Abiomed's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abiomed EV-to-EBIT Chart

Abiomed Annual Data
Trend Mar13 Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 79.87 55.13 24.44 60.31 55.81

Abiomed Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 54.29 61.60 55.81 40.67 40.44

Competitive Comparison of Abiomed's EV-to-EBIT

For the Medical Devices subindustry, Abiomed's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abiomed's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Abiomed's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Abiomed's EV-to-EBIT falls into.



Abiomed EV-to-EBIT Calculation

Abiomed's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=16360.271/254.109
=64.38

Abiomed's current Enterprise Value is $16,360 Mil.
Abiomed's EBIT for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $254 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Abiomed  (NAS:ABMD) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Abiomed's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2022 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2022 ) =EBIT / Enterprise Value (Q: Sep. 2022 )
=254.109/10276.58152
=2.47 %

Abiomed's Enterprise Value for the quarter that ended in Sep. 2022 was $10,277 Mil.
Abiomed's EBIT for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $254 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Abiomed EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Abiomed's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Abiomed (Abiomed) Business Description

Traded in Other Exchanges
N/A
Address
22 Cherry Hill Drive, Danvers, MA, USA, 01923
Abiomed Inc provides temporary mechanical circulatory support devices that are primarily used by interventional cardiologists and heart surgeons. The firm's products are used for patients in need of hemodynamic support before, during, or after angioplasty and heart surgery procedures. Abiomed receives the majority of revenue from its Impella product portfolio, which includes percutaneous micro heart pumps with integration motors and sensors and percutaneous catheter-based axial flow pumps. Abiomed generates the majority of its revenue in the United States.
Executives
Matthew T. Plano officer: VP, GLOBAL OPERATIONS C/O ABIOMED, INC., 22 CHERRY HILL DRIVE, DANVERS MA 01923
Martin P Sutter director 2170 BUCKTHORNE PLACE, SUITE 170, THE WOODLAND TX 77380
David M Weber officer: Chief Operating Officer 2341 ROMANO CIRCLE, PLEASANTON CA 94566
Todd A Trapp officer: Vice President, CFO C/O WATTS WATER TECHNOLOGIES, INC., 815 CHESTNUT STREET, NORTH ANDOVER MA 01845
Michael R Minogue director, officer: President & CEO 22 CHERRY HILL DR, C/O ABIOMED INC, DANVERS MA 01923
Paul Thomas director ONE MILLENNIUM WAY, BRANCHBURG NJ 08876
Paula A Johnson director 22 CHERRY HILL DRIVE, DANVERS MA 01923
Myron L Rolle director 1 NASHUA STREET, APARTMENT 1701, BOSTON MA 02114-1625
Dorothy E Puhy director DANA FARBER CANCER INSTITUTE, 44 BINNEY STREET, RM. D1632, BOSTON MA 02115
Andrew J Greenfield officer: VP Healthcare Solutions 14 HILLSIDE DRIVE, GEORGETOWN MA 01833
Marc A Began officer: VP & General Counsel C/O ABIOMED, INC., 22 CHERRY HILL DRIVE, DANVERS MA 01923
Michael G Howley officer: Vice President 22 CHERRY HILL DRIVE, DANVERS MA 01923
William J Bolt officer: SVP, DA and QA C/O ABIOMED INC, 22 CHERRY HILL DRIVE, DANVERS MA 01923
Rose Eric A Md director 161 FORT WASHINGTON AVENUE, 7TH FLOOR, NEW YORK NY 10032
Henri A Termeer director ONE KENDALL SQUARE, CAMBRIDGE MA 02139